Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive Transfer of Haploidentical NK Cells and ALT-803 in HIV
NCT03899480Phase 1Completed
- Sponsor
- University of Minnesota
- Start
- May 2019
- Primary completion
- Apr 2021
- Modality
- Cytokines & Interferons, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nogapendekin alfa inbakicept and haploidentical natural killer cells in human immunodeficiency virus infection (HIV), sponsored by University of Minnesota. Primary endpoints: Adverse Events, White Blood Cell Count at 21 days and 19 more. Started May 2019; status: completed.
02
Drugs
nogapendekin alfa inbakicepthaploidentical natural killer cells
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03899480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03899480.